Saturday, December 10, 2016 11:02:49 AM
CONJECTURE ON SHORT INTEREST
IMHO, major part of the reduction in short interest is related to the departure of a number of the market-making algos. This occurred contemporaneously with the drop in trading volume.
All market makers, including the algo shops ( they are the only ones left in NNVC and many microcap stocks) carry some short position.
NNVC trading volume has picked up over the last month but most of that can be explained by an increase trading volume in general and in the biotech sector in particular. If the increased volume persists then the algo shops will come back and short interest is likely to pick up again.
I am also of opinion that very little of the short interest has to do with bearish bets. The stock is very hard to borrow. It's mostly professional position to back market-making. If someone wanted to bet on a fall in the stock price and OTC option would be the most economical way to do it. It would also have the advantage of not being vulnerable to a call in on the borrowed stock.
Trendliner
IMHO, major part of the reduction in short interest is related to the departure of a number of the market-making algos. This occurred contemporaneously with the drop in trading volume.
All market makers, including the algo shops ( they are the only ones left in NNVC and many microcap stocks) carry some short position.
NNVC trading volume has picked up over the last month but most of that can be explained by an increase trading volume in general and in the biotech sector in particular. If the increased volume persists then the algo shops will come back and short interest is likely to pick up again.
I am also of opinion that very little of the short interest has to do with bearish bets. The stock is very hard to borrow. It's mostly professional position to back market-making. If someone wanted to bet on a fall in the stock price and OTC option would be the most economical way to do it. It would also have the advantage of not being vulnerable to a call in on the borrowed stock.
Trendliner
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
